News – Page 955 – Endpoints News

Novartis' Sandoz chief is walking out in the middle of a global revamp, fueling fresh buzz about a spinoff

7 years ago

Cambridge's TriNetX raises $40M for clinical analytics platform; NovaBay chops its sales force, appoints new chief

7 years ago

Celgene's chemotherapy Abraxane stumbles in pivotal pancreatic cancer study

7 years ago

Emma Walmsley earns £1M pay rise in her first full year at GSK's helm — but £5.9M package still trails other Big ...

7 years ago

Endpoints News poll: Industry insiders offer a big 👍 for Ned Sharpless

7 years ago

One of the top late-stage drugs Bristol-Myers wants in its $74B Celgene deal faces a ‘roadblock’ — analyst

7 years ago

US lawmakers now want to hear from the middlemen PBMs to unpack their role in drug pricing

7 years ago

Less than a year after Rhopressa launch, Aerie scores new glaucoma drug approval

7 years ago

FDA unveils 5 guidances on broadening cancer clinical trial eligibility

7 years ago

Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the ...

7 years ago

Markets buzz as another mRNA biotech unicorn looks to carry home a record $800M IPO haul

7 years ago

NCI's Ned Sharpless gets the nod to run the FDA in wake of Scott Gottlieb’s surprise exit

7 years ago

Backed by OrbiMed, Lilly and now Advantech, China's InventisBio loads up $70M to propel cancer, metabolic pipeline

7 years ago

Neurocrine breaks out proof-of-concept data for CAH drug; Akebia, MTPC work toward Japanese NDA after anemia drug ...

7 years ago

GeNeuro touts a mixed set of extension data in a shot at salvaging their failed mid-stage MS drug

7 years ago

With Alimta patent cliff looming, Lilly plots stronger foothold in frontline NSCLC with Cyramza

7 years ago

Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100

7 years ago

Trump's White House proposes raft of cuts to science R&D budgets, but FDA scores higher funds

7 years ago

FDA offers quick thumbs up to expand Dupixent's atopic dermatitis label as Regeneron/Sanofi plot blockbuster moves

7 years ago

EMA launches operations in Amsterdam

7 years ago

AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres

7 years ago

Zafgen's second try at Prader-Willi syndrome triggers another safety alarm in preclinical tox study

7 years ago

Is second time the charm for ozanimod? Celgene starts to find out with EMA filing

7 years ago

Takeda touts a landmark head-to-head PhIIIb win over Humira; Allergan's oral CGRP is now under FDA review

7 years ago

First page Previous page 952 953 954955956 957 958 Next page Last page